Hyperreflexia News and Research

RSS

Impact of maternal COVID-19 on neonatal brain development

Researchers described two coronavirus disease 2019 (COVID-19) -infected neonate cases.

10 Apr 2023

COVID-19 and subacute neuropsychiatric symptoms in adolescents

A new paper discusses neurologic symptoms in children with COVID-19.

27 Oct 2021

Study highlights need to educate women and medical community about risk factors of preeclampsia

Despite its crowded healthcare market and strong efforts to make healthcare more accessible to patients, New Jersey has one of the highest maternal mortality rates in the nation-;an issue so pertinent that First Lady Tammy Murphy created the Nurture NJ initiative to help reduce infant and maternal mortality.

20 Sep 2019

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ.

13 Apr 2015

Forest Laboratories, Pierre Fabre Laboratories announce that FETZIMA gets FDA approval for MDD

Forest Laboratories, Inc. and Pierre Fabre Laboratories announced today that FETZIMA (levomilnacipran extended-release capsules), a once-daily serotonin and norepinephrine reuptake inhibitor, discovered by Pierre Fabre Laboratories and co-developed by Forest Laboratories, Inc. was approved by the U.S. Food and Drug Administration for the treatment of Major Depressive Disorder in adults.

26 Jul 2013

Eisai submits BELVIQ NDS with Health Canada

Arena Pharmaceuticals, Inc. announced today that Eisai Limited (based in Mississauga, Ontario), a subsidiary of Eisai Inc., has submitted a New Drug Submission for BELVIQ (lorcaserin HCl) with Health Canada.

26 Jun 2013

Discovery of AVM can relieve pain due to chronic back pain and neurologic deficits

The discovery of a multi-level arteriovenous malformation (AVM) in the thoracic epidural space can now bring relief to potentially thousands of suffers of chronic thoracic pain and progressive myelopothy. Identified as thoracic epidural arteriovenous malformation (T.E.A.M.), this particular AMV primarily affects younger women ages 20 to 40.

27 Oct 2009

Hyperreflexia News and Research

Impact of maternal COVID-19 on neonatal brain development

COVID-19 and subacute neuropsychiatric symptoms in adolescents

Study highlights need to educate women and medical community about risk factors of preeclampsia

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Forest Laboratories, Pierre Fabre Laboratories announce that FETZIMA gets FDA approval for MDD

Eisai submits BELVIQ NDS with Health Canada

Discovery of AVM can relieve pain due to chronic back pain and neurologic deficits

Unlocking the Secrets of Multiple Sclerosis Progression: Brain-Immune Cell Communication

Passing on Polycystic Ovary Syndrome: Health risks for male offspring of women with PCOS

Top-Down Proteomics: Bridging the Genotype-to-Phenotype Gap

Latest News